Radiation recall dermatitis induced by pegylated liposomal doxorubicin

Jimeno, Antonio; Ciruelos, Eva; Castellano, Daniel; Caballero, B.; Rodríguez‐Peralto, José Luis; Cortés, Javier

doi:10.1097/00001813-200308000-00011

Cited by 17 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevailing hypothesis is that the liposomal component of the formulation induces this IgEindependent reaction, and that complement could be important in its pathogenesis. 285 A number of other cutaneous effects are more rarely encountered: exanthems, radiation, ultraviolet light recall, 286,287 and the formation of new melanotic macules on palms and soles unrelated to acral erythema have all been reported. 279,288 The rare intertrigo-like eruption and the scaly follicular eruption with lichenoid histopathology that have been reported require further characterization.…”

Section: Anthracyclinesmentioning

confidence: 99%

Chemotherapeutic agents and the skin: An update

Heidary

Naik

Burgin

2008

Journal of the American Academy of Dermatology

224

138

View full text Add to dashboard Cite

Section: Anthracyclinesmentioning

confidence: 99%

Chemotherapeutic agents and the skin: An update

Heidary

Naik

Burgin

2008

Journal of the American Academy of Dermatology

224

138

View full text Add to dashboard Cite

“…RRD has previously been reported after administration of PLD (8,9) but has never been reported after pre-sensitization. The last fraction of radiotherapy to the left hip was on November 22, 2007.…”

Section: Discussionmentioning

confidence: 93%

Radiation Recall Dermatitis After Pre-Sensitization With Pegylated Liposomal Doxorubicin

Gzell

Carroll

Suchowerska

et al. 2009

Cancer Investigation

View full text Add to dashboard Cite

Radiation recall dermatitis (RRD) is a rare cutaneous reaction occurring within a previously irradiated field, precipitated by certain drugs. We report a case of RRD occurring after pre-sensitization with pegylated liposomal doxorubicin (PLD) in a woman with Stage IV breast cancer. The RRD occurred in one of the patient's four previous radiotherapy fields. We discuss the time/dose factors of radiation exposure and measure the corresponding skin dose. In our case the radiation dose was low and below previously reported thresholds, and illustrates that there is a more complex interaction between the radiotherapy and the trigger agent than has previously been considered.

show abstract

“…[7][8][9] It rapidly follows the introduction of a chemotherapeutic agent including the so-called targeted antineoplastic agents. [10][11][12][13][14][15][16][17] This condition may also develop after administration of other drugs including nonsteroidal antiestrogens, interferon a-2b, simvastatin, and antibacterials. [18][19][20][21] In addition, a similar condition is reported to occur on previous laser treatment sites.…”

Section: Discussionmentioning

confidence: 99%